Investigational drug · Phase 3
NEMO-103
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rotator Cuff Tear, Labral Tear, Rotator Cuff Tendinosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "NEMO-103"
First trial start
2025
Sep 23, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NEMO-103", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rotator Cuff Tear
- Labral Tear
- Rotator Cuff Tendinosis
- Rotator Cuff Tendonitis
- Articular Cartilage Injury
- Glenohumeral Ligament
- Long Head Biceps Tendon Tear
- Adhesive Capsulitis
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "NEMO-103" as an intervention, largest first.
- Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 Injection in Patients With Known or Suspected Shoulder Joint DiseasesPivotal-lookingCompleted
Inventera Inc.Industry
NCT07057037 · 85 participants · Start Sep 23, 2025 · Primary completion Apr 14, 2026
Drug: NEMO-103 Injection · For: Rotator Cuff Tear; Labral Tear; Rotator Cuff Tendinosis and 5 more
Sites: Seongnam-si, South Korea; Seoul, South Korea · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Direct shoulder MR arthrography using an iron-based positive T1 contrast agent (NEMO-103): comparison of image quality with gadolinium-based contrast.
Lee HS, Jang CW, Lee YH, et al. · Sci Rep 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.